The Seville Expert Workshop for Progress in Posttransplant Lymphoproliferative Disorders
| Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
|---|---|
| Data(s) |
01/11/2013
01/11/2013
02/08/2013
|
| Resumo |
Posttransplant lymphoproliferative disorders (PTLDs) are associated with significant morbidity and mortality among solid-organ transplant patients, but approaches to diagnosis and management vary considerably. An international multidisciplinary panel evaluated current understanding of risk factors and classification systems and developed recommendations to aid in PTLD prevention. We considered evidence on PTLD risk factors including Epstein- Barr virus serostatus and immunosuppression and identified knowledge gaps for future research. Recommendations address prophylactic and preemptive strategies to minimize PTLD development, including modulation of immunosuppression and antiviral drug regimens. Finally, new classification criteria were outlined that may help facilitate standardized reporting and improve our understanding of PTLD. Genzyme Genzyme CSL Behring CSL Behring Mundipharma Mundipharma Amgen Amgen Roche Roche BMS BMS Pfizer Pfizer Astellas Astellas Novartis Novartis Fresenius Fresenius |
| Identificador |
TRANSPLANTATION, PHILADELPHIA, v. 94, n. 8, supl. 1, Part 6, pp. 784-793, OCT 27, 2012 0041-1337 http://www.producao.usp.br/handle/BDPI/37386 10.1097/TP.0b013e318269e64f |
| Idioma(s) |
eng |
| Publicador |
LIPPINCOTT WILLIAMS & WILKINS PHILADELPHIA |
| Relação |
TRANSPLANTATION |
| Direitos |
closedAccess Copyright LIPPINCOTT WILLIAMS & WILKINS |
| Palavras-Chave | #EPSTEIN-BARR VIRUS INFECTION #IMMUNOSUPPRESSION #LYMPHOPROLIFERATIVE DISORDER #TRANSPLANTATION #EPSTEIN-BARR-VIRUS #SOLID-ORGAN TRANSPLANTATION #NON-HODGKIN-LYMPHOMA #PEDIATRIC KIDNEY-TRANSPLANTATION #RENAL-TRANSPLANTATION #LIVER-TRANSPLANTATION #RISK-FACTORS #UNITED-STATES #COLLABORATIVE TRANSPLANT #ANTIVIRAL THERAPY #IMMUNOLOGY #SURGERY #TRANSPLANTATION |
| Tipo |
article original article publishedVersion |
